Results 101 to 110 of about 13,099 (221)

Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance

, 2011
BCR-ABL kinase domain (KD) mutations, the most common cause of imatinib resistance, are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) patients.
Riaz ul-Haq, Abdul Qayyum, Mubashar Naqvi, Tariq Gill, Muhammad Khalid, Ammara Tahir, Abid Jamil, Ahmad Khalid, Mahwish Khan, Muhammad Ferhan, Ijaz Shah, Abid Taj, Weng Qin, Mudassar Iqbal, Muhammad Abbad, Aamer Aleem, Tanveer Akhtar, Zafar Iqbal, Najeeb ur-Rehman, Shahid Baig   +19 more
core  

Progression significance for low‐level aberrant B‐lymphoblasts in chronic myeloid leukaemia patients

Clinical and Translational Medicine, Volume 15, Issue 11, November 2025.
Haoren Wang, Huijun Wang, Yuanyuan Li, Bin Zheng, Qiuyun Fang, Yan Li, Yuntao Liu, Runxia Gu, Ying Wang, Yingchang Mi, Bingcheng Liu, Hui Wei, Jianxiang Wang   +12 more
wiley   +1 more source

TREATMENT WITH IMATINIB MESILAT IN CHRONIC MYELOGENOUS LEUKEMIA – OUR EXPERIENCE

Zdravniški Vestnik, 2004
Background. Chronic myelogenous leukemia (CML) is a malignant clonal disorder of hematopoietic stem cell. In majority of patients we find reciprocal chromosomal translocation t (9.22) which result in fusion oncoprotein with tyrosine kinase activity.
Mateja Grat, Joško Vučkovič
doaj  

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Elucidating the role of the tumor suppressor Protein Phoshatase 2A in Chronic Myeloid Leukemia.

, 2010
Protein phosphatase-2A (PP2A) is one of the major cellular serine-threonine phosphatases and is involved in the regulation of cell homeostasis through the negative regulation of signaling pathways initiated by protein kinases.
Neviani, Paolo
core  

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Unravelling the mechanisms of resistance to imatinib mesylate in chronic myeloid leukemia: a proteomic approach

, 2010
Imatinib mesylate is a potent inhibitor of the Bcr-Abl tyrosine kinase, an oncoprotein that plays a key role in the development of chronic myeloid leukemia. Consequently, imatinib is used as front-line therapy for this disease.
Colavita, Irene
core  

Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS [PDF]

, 2011
The LC-ESI-MS was developed and validated for the analysis of imatinib in plasma and bone marrow samples using deuterated imatinib (D(8)-IM) as an internal standard. The biological samples were extracted using Strata-X-C SPE cartridges and separated on C&
Holyoake, T.L., Iqbal, Zafar, Jorgensen, H.G., Watson, David, Holyoake, Tessa, Elliott, M., Elliott, Moira, Iqbal, Z., Jørgensen, Heather, Watson, D.G.   +9 more
core  

Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital

Revista Brasileira de Hematologia e Hemoterapia, 2013
Objetive: The aim of this study was to identify the reasons for failure in adherence to imatinib mesylate treatment in chronic myeloid leukemia. Methods: A retrospective review was performed of
Samuel Roosevelt Campos dos Reis, Acy Telles de Souza Quixada, Sammara Tavares Nunes, Danielle Maria Camelo Cid, Jacqueline Holanda de Souza, Clara Maria Bastos Eloy da Costa, Carolina Bizelli Silveira, David Antonio Camelo Cid, Mariana Fatima Cabral de Oliveira   +8 more
doaj   +1 more source

Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia

, 2001
Chronic myeloid leukemia (CML) is characterized by formation of the BCR-ABL fusion gene, usually as a consequence of the Philadelphia (Ph) translocation between chromosomes 9 and 22.
Reid, AG, Campbell, LJ, Telford, N, Grace, C, Nacheva, EP, Shepherd, P, Szer, J, Green, AR, Bench, AJ, Prince, HM, Huntly, BJP, Turner, P   +11 more
core